Utidelone
Drug for treatment of breast cancer
From Wikipedia, the free encyclopedia
Utidelone is a pharmaceutical drug for the treatment of metastatic breast cancer. It was approved for use in China in 2021.[1][2]
| |
| Clinical data | |
|---|---|
| Trade names | 優替帝 |
| Other names | Epothilone D; desoxyepothilone B |
| ATC code | |
| Legal status | |
| Legal status |
|
| Identifiers | |
| CAS Number | |
| PubChem CID | |
| DrugBank | |
| UNII | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C27H41NO5S |
| Molar mass | 491.69 g·mol−1 |
Utidelone is a member of the epothilone class of natural products, which are metabolites produced by the soil-dwelling myxobacterium Sorangium cellulosum.[3] It is also known as epothilone D.
